Don't take this it will be poi-To The Moon - Tiger Brokers Online Investing Community - To The Moon

4
Comment
Favorite

Large Caps
06-29

Don't take this it will be poison

Moderna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel

Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus vaccine for adults aged 60 and older. The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. “mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a p

Moderna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

4

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":321823637770416,"tweetId":"321823637770416","gmtCreate":1719600707173,"gmtModify":1719600712139,"author":{"id":4161990869312902,"idStr":"4161990869312902","authorId":4161990869312902,"authorIdStr":"4161990869312902","name":"Large Caps","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>Don't take this it will be poison</p></body></html>","htmlText":"<html><head></head><body><p>Don't take this it will be poison</p></body></html>","text":"Don't take this it will be poison","highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/321823637770416","repostId":2446450819,"repostType":4,"repost":{"id":"2446450819","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1719575100,"share":"https://www.laohu8.com/m/news/2446450819?lang=&edition=full","pubTime":"2024-06-28 19:45","market":"us","language":"en","title":"Moderna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2446450819","media":"Dow Jones","summary":"Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus  vaccine for adults aged 60 and older. The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. “mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a p","content":"<html><head></head><body><p>Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. </p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3beebd0423ab3a8cd18c9812cd1f33f1\" tg-width=\"865\" tg-height=\"626\"/></p><p>The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. </p><p>“mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors,” Moderna CEO Stéphane Bancel said in prepared remarks. </p><p>RSV often causes mild, cold-like symptoms, but can be severe, particularly for infants and older adults. About 60,000 to 160,000 people age 65 and older are hospitalized each year due to RSV, according to the Centers for Disease Control and Prevention. </p><p>The stock has gained 22% in the year to date, outperforming the S&amp;P 500, which has gained 15%.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna’s RSV Vaccine Gets Positive Opinion from EU Advisory Panel\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-06-28 19:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. </p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3beebd0423ab3a8cd18c9812cd1f33f1\" tg-width=\"865\" tg-height=\"626\"/></p><p>The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. </p><p>“mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors,” Moderna CEO Stéphane Bancel said in prepared remarks. </p><p>RSV often causes mild, cold-like symptoms, but can be severe, particularly for infants and older adults. About 60,000 to 160,000 people age 65 and older are hospitalized each year due to RSV, according to the Centers for Disease Control and Prevention. </p><p>The stock has gained 22% in the year to date, outperforming the S&amp;P 500, which has gained 15%.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BK4551":"寇图资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4532":"文艺复兴科技持仓","BK4156":"煤与消费用燃料","BK4548":"巴美列捷福持仓","BK4501":"段永平概念","BK4534":"瑞士信贷持仓","BK4568":"美国抗疫概念","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BK4588":"碎股"},"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2446450819","content_text":"Moderna Inc.’s stock rose 1.1% early Friday, after the biotech said an advisory panel to the European Union’s medical regulator had adopted a positive opinion on its respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. The vaccine called mResvia has already been approved by the U.S. Food and Drug Administration, becoming Moderna’s second approved product after its COVID-19 vaccine, Spikevax. “mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can save healthcare professionals time and reduce administrative errors,” Moderna CEO Stéphane Bancel said in prepared remarks. RSV often causes mild, cold-like symptoms, but can be severe, particularly for infants and older adults. About 60,000 to 160,000 people age 65 and older are hospitalized each year due to RSV, according to the Centers for Disease Control and Prevention. The stock has gained 22% in the year to date, outperforming the S&P 500, which has gained 15%.","news_type":1},"isVote":1,"tweetType":1,"viewCount":69,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":27,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}